Free Trial
NASDAQ:PETV

PetVivo Earnings Date & Estimates

PetVivo logo
$0.56 -0.02 (-2.59%)
As of 01:45 PM Eastern

PetVivo is estimated to report earnings on Thursday, November 12, 2026.

What Analysts Expect from PetVivo

PetVivo is expected to post earnings of -$0.08 per share on revenue of $5 thousand.

Consensus Estimates

Consensus EPS
-$0.08
Expected Revenue
$5 thousand

Recent Track Record

Last Reported
Q1 2025
Last Quarter EPS
-$0.11
Last Quarter Revenue
$120 thousand

PetVivo Earnings FAQ

PetVivo (NASDAQ:PETV) is estimated to report earnings on Thursday, November 12, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect PetVivo to post earnings of -$0.08 per share for the quarter.

The consensus revenue estimate for PetVivo is $5 thousand for the quarter.

PetVivo Earnings Headlines

The warning signs most investors see too late
Dr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008.tc pixel
Jaime Pickett Joins PetVivo Holdings, Inc. Board of Directors
Michael Handley Joins PetVivo Holdings, Inc. Board of Directors
See More PetVivo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PetVivo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PetVivo and other key companies, straight to your email.

About PetVivo

PetVivo (NASDAQ:PETV) is a biomedical company focused on developing and commercializing medical therapeutics and devices for use in animals and, potentially, humans. The company’s technologies are designed to address conditions involving damaged or diseased tissue, with an emphasis on minimally invasive treatments.

PetVivo’s principal commercial product is Spryng with OsteoCushion Technology, an injectable product administered by veterinary professionals. It is intended to help manage lameness associated with osteoarthritis and other joint-related conditions in animals, including dogs and horses. The company continues to develop additional products based on its proprietary platform for regenerative and tissue-support applications.

Based in Minneapolis, Minnesota, PetVivo primarily serves the veterinary healthcare market through animal-health professionals and related distribution channels. John Lai serves as the company’s chief executive officer. The company has also indicated that its technologies may have future applications in human healthcare, subject to further development and regulatory approval.

View PetVivo Profile